This segment focuses on the development and commercialization of therapeutics for the treatment of Opioid Use Disorder (OUD). The primary product in this segment is Probuphine, a buprenorphine implant utilizing the ProNeura long-term drug delivery platform. Research and development activities include clinical trials to support Probuphine's use and exploring new applications of the ProNeura technology. The segment addresses the significant patient impact of OUD by providing a sustained-release medication to help patients maintain stability and reduce relapse rates. Market positioning involves partnerships with specialty pharmacies like AllianceRx Walgreens Prime to improve patient access. Future opportunities include expanding Probuphine's availability and exploring the Nalmefene implant program for preventing opioid relapse. Regulatory aspects involve FDA approval and compliance with relevant guidelines. This segment aims to improve patient outcomes and reduce the societal burden of opioid addiction.

This segment is dedicated to the development of treatments for chronic pruritus (severe, persistent itching). The primary focus is on the kappa opioid agonist peptide program, TP-2021, which is being developed for use in combination with the ProNeura technology. Research and development efforts include preclinical studies and clinical trials to evaluate the efficacy and safety of TP-2021. The segment addresses the significant unmet medical need for effective treatments for chronic pruritus, which can severely impact patients' quality of life. Market positioning involves leveraging the ProNeura platform's advantages in sustained drug delivery. Future opportunities include expanding the clinical development of TP-2021 and exploring potential applications in other dermatological conditions. Regulatory aspects involve obtaining necessary approvals from regulatory bodies. The segment aims to provide innovative solutions for patients suffering from chronic pruritus, improving their comfort and well-being.

This segment encompasses the ongoing development and refinement of the ProNeura long-term drug delivery platform. Research and development activities include exploring new applications of the platform for various therapeutic areas, including malaria prophylaxis. The technology utilizes a proprietary implantable system to deliver drugs continuously over extended periods. This segment focuses on improving drug efficacy, reducing side effects, and enhancing patient adherence. Market positioning involves leveraging the platform's unique capabilities to create sustained-release formulations for various chronic diseases. Future opportunities include expanding the platform's applications and partnering with other pharmaceutical companies to develop new products. Regulatory aspects involve obtaining necessary approvals for new drug formulations and delivery systems. The segment aims to provide a versatile platform for improving drug delivery and patient outcomes across a wide range of therapeutic areas.